Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVSNASDAQ:APLTNYSE:ATNMNASDAQ:FWP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.82-4.3%$1.89$1.11▼$17.88$54.76M1.62740,647 shs371,950 shsAPLTApplied Therapeutics$0.35-3.0%$0.39$0.30▼$10.62$50.12M1.863.38 million shs1.09 million shsATNMActinium Pharmaceuticals$1.49-6.3%$1.50$1.03▼$8.64$46.48M-0.27505,432 shs489,218 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio-4.58%-11.98%+65.10%+63.19%-53.70%APLTApplied Therapeutics-3.01%-4.12%-27.04%-31.05%-93.28%ATNMActinium Pharmaceuticals-6.29%-18.58%+2.05%+21.14%-81.72%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio2.0704 of 5 stars3.51.00.00.02.61.70.6APLTApplied Therapeutics4.2584 of 5 stars3.33.00.04.73.41.70.6ATNMActinium Pharmaceuticals1.1969 of 5 stars3.42.00.00.00.00.00.6FWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 3.00Buy$30.25974.60% UpsideAPLTApplied Therapeutics 2.50Moderate Buy$6.101,623.16% UpsideATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00168.46% UpsideFWPForward Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FWP, ANVS, ATNM, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.005/14/2025APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.505/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/18/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AAPLTApplied Therapeutics$265K189.12N/AN/A($0.20) per share-1.77ATNMActinium Pharmaceuticals$81K573.85N/AN/A$1.31 per share1.14FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$2.16N/AN/AN/AN/AN/A-311.00%8/13/2025 (Estimated)APLTApplied Therapeutics-$119.76M-$0.43N/AN/AN/AN/A-260.75%-76.04%8/6/2025 (Estimated)ATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/AFWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALatest FWP, ANVS, ATNM, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/21/2025Q4 2024ANVSAnnovis Bio-$0.38-$0.43-$0.05-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.662.66APLTApplied TherapeuticsN/A1.061.06ATNMActinium PharmaceuticalsN/A10.2510.25FWPForward Pharma A/SN/A18.43N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%APLTApplied Therapeutics98.31%ATNMActinium Pharmaceuticals27.50%FWPForward Pharma A/S12.57%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%APLTApplied Therapeutics1.60%ATNMActinium Pharmaceuticals6.00%FWPForward Pharma A/S71.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million9.64 millionOptionableAPLTApplied Therapeutics30141.58 million106.35 millionOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableFWP, ANVS, ATNM, and APLT HeadlinesRecent News About These CompaniesInside Forward's failed attempt to revolutionize the doctor's officeNovember 14, 2024 | businessinsider.comPrimary care player Forward shutters after raising $400M, rolling out CarePodsNovember 13, 2024 | fiercehealthcare.comForward shuts down one year after $100M funding roundNovember 13, 2024 | modernhealthcare.comPharma’s ethically questionable sites essentially sell drugs directly to consumersNovember 6, 2024 | statnews.comU.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain PartnersNovember 1, 2024 | msn.comPharmalittle: We’re reading about disappointing Lilly sales, a Roche Alzheimer’s therapy, and moreOctober 30, 2024 | statnews.comSangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory DevelopmentOctober 23, 2024 | seekingalpha.comWhy developers are turning to Forward Factory’s Code-to-Earn model (And why you should too)October 23, 2024 | msn.comFinland's largest energy company files €800 million lawsuit against RussiaOctober 22, 2024 | msn.comFirebrick Pharma’s Strategic Moves Boost Market PositionOctober 22, 2024 | markets.businessinsider.comThis Podiatrist Closed The $30 Million Gap Between Orthopedic And Fashion-Forward FootwearOctober 22, 2024 | forbes.comForward Air retains investment bankers to sell company, sources sayOctober 17, 2024 | freightwaves.comPharma 4.0: Shaping the Future of Pharmaceutical ManufacturingOctober 16, 2024 | news-medical.netIn the competitive world of pharma, companies need to focus on worker well-being to retain top talent, says Ferring's HR execOctober 16, 2024 | msn.comWest Pharmaceutical Services Honored with Heart of Pharma Award for Cancer PartnershipOctober 13, 2024 | msn.comFERMWORX Receives Department of Defense Award to Strengthen U.S. Supply Chains Through Bioindustrial ManufacturingOctober 11, 2024 | tmcnet.comForward Air ticks higher as activist Alta Fox pushes for strategic reviewOctober 8, 2024 | msn.comIronwood Pharmaceuticals: A Strong Buy on Financial Fortitude and Pipeline ProgressSeptember 30, 2024 | markets.businessinsider.comWIN Announces ‘Pay It Forward’ CampaignSeptember 26, 2024 | aftermarketnews.comFTC sues Big Pharma middlemen over skyrocketing insulin prices, targeting PBM practicesSeptember 25, 2024 | nationofchange.orgNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFWP, ANVS, ATNM, and APLT Company DescriptionsAnnovis Bio NYSE:ANVS$2.82 -0.13 (-4.25%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$2.92 +0.11 (+3.91%) As of 06/13/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Applied Therapeutics NASDAQ:APLT$0.35 -0.01 (-3.01%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.36 +0.01 (+1.98%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Actinium Pharmaceuticals NYSE:ATNM$1.49 -0.10 (-6.29%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.49 0.00 (0.00%) As of 06/13/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Forward Pharma A/S NASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
